title: CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).
abstract: CD26 is a surface glycoprotein with intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity with multiple biological roles, including being intricately involved in immunoregulation as a T-cell activation molecule and as a regulator of chemokine function. T-cell lymphoid malignancies represent a heterogeneous group of diseases that are generally aggressive and are for the most part resistant to current treatment modalities. Previous studies showed that CD26 is expressed on selected T-cell neoplasms, suggesting a potential role for CD26 in tumor development. We review herein recent classification schemes for T-cell lymphoid malignancies that take into account various facets of their clinical presentation. In addition, we discuss findings supporting the conclusion that CD26 has an essential role in human T-cell activation, as well as its ability to regulate the biological effects of selected chemokines through its DPPIV activity. Finally, we will present recent work from our laboratory that indicates a potential role for CD26 as a molecular target for novel treatment modalities for T-cell lymphoid malignancies.
authors.affiliation: Department of Lymphoma/Myeloma, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Kazuya
authors.initials: K
authors.lastname: Sato
authors.forename: Nam H
authors.initials: NH
authors.lastname: Dang
mesh_terms: D058892:Adenosine Deaminase Inhibitors; D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000187:drug effects / Q000502:physiology*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology; D002986:Clinical Trials as Topic; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects / Q000502:physiology*; D004317:Doxorubicin / Q000494:pharmacology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019169:Jurkat Cells / Q000201:enzymology; D015458:Leukemia, T-Cell / Q000145:classification / Q000188:drug therapy* / Q000201:enzymology; D008213:Lymphocyte Activation / Q000502:physiology*; D008211:Lymphocyte Cooperation / Q000502:physiology*; D016399:Lymphoma, T-Cell / Q000145:classification / Q000188:drug therapy* / Q000201:enzymology; D008232:Lymphoproliferative Disorders / Q000188:drug therapy / Q000201:enzymology; D051379:Mice; D016513:Mice, SCID; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D015649:Pentostatin / Q000494:pharmacology / Q000627:therapeutic use; D011379:Prognosis; D014162:Transfection; D014944:World Health Organization
chemical_list: D058892:Adenosine Deaminase Inhibitors; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D015649:Pentostatin; D004317:Doxorubicin; D018819:Dipeptidyl Peptidase 4